Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects

L. Caggiari, S. Zanussi, C. Crepaldi, M. T. Bortolin, C. Caffau, M. D'Andrea, P. De Paoli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. Methods: We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. Results: Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. Conclusions: Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalCytometry
Volume44
Issue number4
Publication statusPublished - Aug 15 2001

Fingerprint

Interleukin-2
Cell Proliferation
HIV
T-Lymphocytes
Highly Active Antiretroviral Therapy
CD4-CD8 Ratio
CD4 Lymphocyte Count
Ki-67 Antigen
Lymphocyte Subsets
Flow Cytometry
Observation
Lymphocytes
Therapeutics

Keywords

  • CD4
  • CD8
  • HIV
  • IL-2 therapy
  • Ki67

ASJC Scopus subject areas

  • Hematology
  • Cell Biology
  • Pathology and Forensic Medicine
  • Biophysics
  • Endocrinology

Cite this

Caggiari, L., Zanussi, S., Crepaldi, C., Bortolin, M. T., Caffau, C., D'Andrea, M., & De Paoli, P. (2001). Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects. Cytometry, 44(4), 233-237.

Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects. / Caggiari, L.; Zanussi, S.; Crepaldi, C.; Bortolin, M. T.; Caffau, C.; D'Andrea, M.; De Paoli, P.

In: Cytometry, Vol. 44, No. 4, 15.08.2001, p. 233-237.

Research output: Contribution to journalArticle

Caggiari, L, Zanussi, S, Crepaldi, C, Bortolin, MT, Caffau, C, D'Andrea, M & De Paoli, P 2001, 'Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects', Cytometry, vol. 44, no. 4, pp. 233-237.
Caggiari L, Zanussi S, Crepaldi C, Bortolin MT, Caffau C, D'Andrea M et al. Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects. Cytometry. 2001 Aug 15;44(4):233-237.
Caggiari, L. ; Zanussi, S. ; Crepaldi, C. ; Bortolin, M. T. ; Caffau, C. ; D'Andrea, M. ; De Paoli, P. / Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects. In: Cytometry. 2001 ; Vol. 44, No. 4. pp. 233-237.
@article{e7032d6fd95e46bfbc474e5fbe67910f,
title = "Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects",
abstract = "Background: Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. Methods: We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. Results: Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. Conclusions: Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens.",
keywords = "CD4, CD8, HIV, IL-2 therapy, Ki67",
author = "L. Caggiari and S. Zanussi and C. Crepaldi and Bortolin, {M. T.} and C. Caffau and M. D'Andrea and {De Paoli}, P.",
year = "2001",
month = "8",
day = "15",
language = "English",
volume = "44",
pages = "233--237",
journal = "Cytometry Part B - Clinical Cytometry",
issn = "1552-4949",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects

AU - Caggiari, L.

AU - Zanussi, S.

AU - Crepaldi, C.

AU - Bortolin, M. T.

AU - Caffau, C.

AU - D'Andrea, M.

AU - De Paoli, P.

PY - 2001/8/15

Y1 - 2001/8/15

N2 - Background: Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. Methods: We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. Results: Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. Conclusions: Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens.

AB - Background: Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. Methods: We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. Results: Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. Conclusions: Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens.

KW - CD4

KW - CD8

KW - HIV

KW - IL-2 therapy

KW - Ki67

UR - http://www.scopus.com/inward/record.url?scp=0035880444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035880444&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 233

EP - 237

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

SN - 1552-4949

IS - 4

ER -